Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Announces Plans for IPO in the US

Premium

T

EL AVIV--Compugen announced plans to make an initial public offering in the US this year to support the expansion of its genetic R&D methods, according to a Dow Jones Newswire report. The company, which has identified more than 14,000 genes and gene sequences, has licensed its bioinformatics technologies to American Home ProductsWyeth-Ayerst division, Amgen, Bayer, Eli Lilly, Merck, Parke-Davis, and SmithKline Beecham. Compugen also recently announced the launch of an online research portal, LabOnWeb.com. Venture capital firms, including US Venture Partners, have invested $25 million in the company.

Part of Compugen’s gene discovery technology involves modeling where and how the first genes were found, something that the company contended is a more efficient method than other approaches. "It’s like oil exploration," said chairman Martin Gerstel in the news report. "All the other oil companies are hitting oil, but we’re creating a model based on how the first geyser was discovered."

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.